Cookies help to improve your website experience and provide secure services. Some cookies are essential for security and login functionalities, others enable easier use and convenient support. You can revoke your decision at any time.
A product clinically proven to be effective and efficient – LymphaTouch is certified as an ISO1385 compliant medical device manufacturer, and the device has received CE and US FDA medical device approval.
A solution to a prevalent problem – LymphaTouch treatment improves treatment outcomes and allows the therapist to work more effectively. The device therapy supports manual therapy and together save the practitioner's hands and time. Versatile application areas offer the possibility to expand the range of services.
Scalable business model – LymphaTouch's network of distributors covers around 30 countries.
Strategic partnerships – Strategic and beneficial partnerships allows the company to accelerate access to new markets, leverage on technology and expertise, and reach a wide range of customers.
„LymphaTouch is reshaping rehabilitation and lymphatic therapy, enabling faster recovery and effective relief. Our patented CE marked medical devices have helped many people suffering from injuries, swelling and pain. With a focus on global expansion and continuous innovation, we present a compelling investment opportunity as we transform patient care worldwide. Join us in creating a meaningful impact on healthcare outcomes while building a great partnership. "
Janne Matikainen, CEO
LymphaTouch Oy (LymphaTouch) was founded in 2005 out of a desire to help patients with lymphatic and circulatory problems by using innovative vacuum technology. The company provides easy-to-use and effective solutions for patients recovering from e.g. breast cancer treatments, sport injuries, post surgery swelling or scars.
LymphaTouch is certified as an ISO13485 compliant medical device manufacturer and has received CE and US FDA medical device approval.
LymphaTouch's current owners include Innovestor, one of Finland's largest private equity firms, and a number of well-known angel investors. LymphaTouch's Board is chaired by Leena Niemistö, MD, specialist in physiatry and government professional. The company's key people form a diverse and experienced team, combining many years of experience in the health technology sector and its sub-sectors.
In 2023, LymphaTouch signed a major technology collaboration agreement with Mego Afek of Israel. This partnership agreement opens the door to a whole new market and creates unprecedented opportunities in the company's history.
Mego Afek's strong network and international presence provide LymphaTouch with a unique opportunity to expand globally and reach healthcare professionals and patients in new regions. By combining resources and expertise, LymphaTouch and Mego Afek will create synergies that will strengthen both companies' position as pioneers in health technology.
This technology partnership agreement not only expands LymphaTouch's business opportunities, but also supports the company's mission to bring relief and improve the quality of life for patients worldwide.
LymphaTouch Light "LT-01":
For medical professionals, e.g. physiotherapists, to treat patients with a wide range of pain and swelling related conditions.
LymphaTouch Pro "LT-02":
The newest addition to the company's portfolio, the LT-02 incorporates all the proven features of the LT-01, but has also received numerous improvements in design and materials. The device will replace LT-01 in professional use. Designed for heavy users in challenging conditions
Accessories:
Exchange cups: LymphaTouch offer exchange cups of different sizes and shapes that can be adapted to different treatment needs and areas.
Filters: High quality filters ensure that your device will work optimally and improve hygiene.
Cart: Designed to make it easy to move and store your device, our cart is specifically designed for LymphaTouch Light devices.
Following the general best practice of medical device industry, LymphaTouch outsources the majority of sales and distribution. The team does direct sales only in the domestic market, and use local distributors elsewhere. This secures scalability and accelerates LymphaTouch's time to market, as the selected distributors already have access to thousands of potential buyers worldwide.
The target customers are 1.6 million physiotherapists worldwide. LymphaTouch's customers include healthcare professionals who specialize in manual therapy, such as physiotherapists, occupational therapists, lymph specialists, and other practitioners in the healthcare field.
Most of the sales consist of device sales. The purchase of a device is usually a one-off investment, but often there may be a need to upgrade or replace it, for example when a newer model becomes available or the device reaches the end of its life.
As install base grows, so does the need and demand for maintenance services. This means that after-sales services can account for a significant proportion of recurring sales, especially when customers want to ensure the functionality and longevity of their device. Sales of cups and filters are recurring sales and their demand is growing in proportion to the devices in active use.
Distributors
The company is active in the physiotherapy equipment market, which is expanding rapidly due to factors such as an aging population, increasing rates of cancer, and rising levels of obesity. The initial total addressable market is nearly € 400 million focused on lymphedema treatment. Thanks to the versatility of LymphaTouch's core technology the company can target the overall physiotherapy equipment market valued well over € 20 billion.
The global physiotherapy equipment market size reached US$ 16.5 billion in 2021. Looking ahead, it is anticipated that the market will grow at a Compound Annual Growth Rate (CAGR) of 6.44% between 2021 and 2027, reaching US$ 24.0 billion by the end of the forecast period.
Chair of the Board
Member of the Board
Member of the Board
CEO
Sales Director
Clinical specialist
LymphaTouch Oy is a limited liability company with a subsidiary in the United States, LymphaTouch Inc.
Innovestor Growth Fund I KY, Gerago Oy and Takoa Growth Oy are the main shareholders of Lymphatouch which collectively possess around 44% of shares. The current Board of Directors owns approximately 67%.
Shareholder |
Shares |
Votes |
|
|---|---|---|---|
| 1 | Innovestor Kasvurahasto I KY | 130,988 | 18.9 % |
| 2 | Gerako Oy | 111,000 | 16.0 % |
| 3 | Stig Gustavson | 71,095 | 10.3 % |
| 4 | Takoa Growth Oy | 64,141 | 9.3 % |
| 5 | Acme Investments SPF S.a.r.l. | 61,125 | 8.8 % |
| 6 | Leena Niemistö | 59,069 | 8.5 % |
| 7 | Heliocabala Oy | 51,121 | 7.4 % |
| 8 | Ventic Oy | 28,899 | 4.2 % |
| 9 | Pertti Kärkkäinen | 21,943 | 3.2 % |
| 10 | Other shareholders (37) | 92,266 | 13.3% |
| TOTAL | 691,647 | 100 % |
(€1M collected in the financing round)
(€600,000 collected in the financing round)
(€300,000 collected in the financing round)
You can find more detailed information about the company in the information memorandum.
The information memorandum is provided by the company.
Customer loyalty and long-term customer relationships are key factors that create stability and predictability in the company's revenues. One of LymphaTouch's greatest strengths is its rich clinical evidence base.
The company's ability to understand the market, innovate and forge strategic partnerships has given it a solid position as a pioneer in the health technology sector. Accordingly, the company's valuation was estimated to be € 2 628 258,60 in August 2023.
Increase in demand, loyal customers, and expansion of LymphaTouch's product portfolio with the new LymphaTouch Pro open up new markets for the company.
In addition, LymphaTouch's signed partnership agreement with MegoAfek will open up new business opportunities for the company and allow synergies for both parties.
Sales through acquisition are expected to be the optimal and most probable choice. The company's sale was discussed in 2022. LymphaTouch will be ready for commercial sale once the company's cash flow demonstrates positivity.
An IPO is a potential avenue for financing. When LymphaTouch Pro manages to establish itself and achieve a revenue growth of $5-6 million, an IPO could become a feasible method of gathering more funding for future business expansion and product portfolio development.
Private equity investment is a third viable option when a company's cash flow is positive and steadily growing.
Q: How much growth does LymphaTouch Oy expect in the next five years?
A: LymphaTouch's five year strategy is presented here.
---
LymphaTouch is organising a webinar in Finnish on Wednesday 27 September at 9.00 am, with speakers Leena Niemistö, Stig Gustavson and Janne Matikainen.
Leena Niemistö and Stig Gustavson, well-known business profiles and business angels talks about the latest in Finnish rehabilitation technology and about LymphaTouch Oy as an investment opportunity.
---
New information will be added to this section regularly as funding progresses. To be informed about new updates in a timely manner, subscribe to our newsletter.
You can reach us by mail, by phone and via our chat.
+358 20 735 25 90
You will find the chat in the bottom right corner.
In our FAQ section you will find answers to frequently asked questions.
